Dan Carroll

Dan Carroll

TMFCane

Dan began writing for the Motley Fool in 2012. He is a health care specialist who also follows the defense industry along with tracking the broader U.S. and international markets.

Recent articles




The 5 Richest States in America

Residents of these five chart-toppers out-earn their peers nationwide, but will these states' economies keep up?


The 5 Richest Countries in the World

These five nations have overcome the recession and prospered. But what makes them wealthy while other countries struggle?


3 Best Stocks to Invest in Pharma

AbbVie, Novo Nordisk, and Johnson & Johnson are three top healthcare stocks poised to delight investors for years to come



3 Reasons Zimmer Holdings Inc.'s Stock Could Rise

Zimmer Holdings has underperformed its top orthopedic device competitors year to date, but this medical device leader could be poised for a big rebound in the years to come


3 Reasons Mylan Inc Stock Could Rise

Mylan has underperformed against other leading generic drug stocks in 2014, but that could change in the near future

Visa Sinks the Dow Jones

Pandora also dives on earnings worries in a downbeat end to the week for investors.





Pfizer's Incoming Patent Cliff

Pfizer's loss of Lipitor's patent in 2012 slammed this top pharma stock. Will losses of Lyrica and other top drugs in coming years offer a repeat performance?